OTCMKTS:GNMSF

Genmab A/S (GNMSF) Stock Price, News & Analysis

Genmab A/S logo
$503.74 -18.06 (-3.46%)
As of 02:53 PM Eastern

About Genmab A/S Stock (OTCMKTS:GNMSF)

Advanced

Key Stats

Today's Range
$503.74
▼
$503.74
50-Day Range
$329.25
▼
$580.00
52-Week Range
$232.34
▼
$581.00
Volume
131 shs
Average Volume
2,732 shs
Market Capitalization
$31.02 billion
P/E Ratio
42.69
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on treatments for cancer and other serious diseases.

The company uses its antibody technologies, including DuoBody and HexaBody, to develop therapeutic candidates and works with pharmaceutical partners to advance and commercialize medicines. Products developed through Genmab programs include Darzalex, Tecvayli, Epkinly/Tepkinly and Rybrevant, which are marketed through partnerships.

Genmab conducts research and development internationally, with operations in Europe, North America and Asia. The company is led by President and Chief Executive Officer Jan van de Winkel, who co-founded Genmab.

AI Generated. May Contain Errors.

Genmab A/S Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
14th Percentile Overall Score

GNMSF MarketRank™: 
0.682810368345 of 5 stars

Genmab A/S scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Genmab A/S.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Genmab A/S is 42.69, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.70.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Genmab A/S is 42.69, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.83.

  • Price to Book Value per Share Ratio

    Genmab A/S has a P/B Ratio of 5.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.12% of the float of Genmab A/S has been sold short.
  • Short Interest Ratio / Days to Cover

    Genmab A/S has a short interest ratio ("days to cover") of 4.35.
  • Change versus previous month

    Short interest in Genmab A/S has recently decreased by 6.06%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Genmab A/S does not currently pay a dividend.

  • Dividend Growth

    Genmab A/S does not have a long track record of dividend growth.

  • News Sentiment

    Genmab A/S has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • Insider Buying vs. Insider Selling

    In the past three months, Genmab A/S insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    1.54% of the stock of Genmab A/S is held by insiders.

  • Percentage Held by Institutions

    Genmab A/S has minimal institutional ownership at this time.

  • Read more about Genmab A/S's insider trading history.
Receive GNMSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GNMSF Stock News Headlines

Genmab Files Articles of Association Dated November 10
Genmab Reports November 10 Executive Share Sales
You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
Genmab Gains After Phase 3 Ovarian Cancer Win for Rina-S
GMAB jumps as Genmab posts positive Phase 3 lymphoma data
See More Headlines

GNMSF Stock Analysis - Frequently Asked Questions

Genmab A/S's stock was trading at $314.00 at the start of the year. Since then, GNMSF shares have increased by 60.4% and is now trading at $503.7388.

Genmab A/S (OTCMKTS:GNMSF) released its quarterly earnings data on Tuesday, February, 17th. The company reported $0.55 EPS for the quarter, missing the consensus estimate of $3.10 by $2.55. The business had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.05 billion. Genmab A/S had a net margin of 16.97% and a trailing twelve-month return on equity of 13.96%.

Shares of GNMSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Genmab A/S investors own include Genmab A/S (GMAB), Novo Nordisk A/S (NVO), Bavarian Nordic (BVNRY), GENMAB A/S/S (GMXAY), Micron Technology (MU), Alibaba Group (BABA) and Cigna Group (CI).

Company Calendar

Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
OTCMKTS:GNMSF
CIK
1434265
Employees
3,029
Year Founded
1999

Profitability

EPS (Trailing Twelve Months)
$11.80
Trailing P/E Ratio
42.69
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$963 million
Net Margins
16.97%
Pretax Margin
21.93%
Return on Equity
13.96%
Return on Assets
6.47%

Debt

Debt-to-Equity Ratio
0.81
Current Ratio
2.46
Quick Ratio
2.44

Sales & Book Value

Annual Sales
$3.72 billion
Price / Sales
8.34
Cash Flow
$15.31 per share
Price / Cash Flow
32.91
Book Value
$88.49 per share
Price / Book
5.69

Miscellaneous

Outstanding Shares
61,570,000
Free Float
60,622,000
Market Cap
$31.02 billion
Optionable
Not Optionable
Beta
0.64

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (OTCMKTS:GNMSF) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners